- Home
- MMI vs XNCR Comparison
MMI vs XNCR Comparison
Compare MMI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMI | XNCR |
|---|---|---|
| Founded | 1971 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MMI | XNCR |
|---|---|---|
| Price | $27.85 | $16.53 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $29.00 | $22.44 |
| AVG Volume (30 Days) | 413.1K | ★ 738.7K |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $751,284,000.00 | $150,132,000.00 |
| Revenue This Year | $11.94 | $18.81 |
| Revenue Next Year | $15.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.74 | ★ 38.16 |
| 52 Week Low | $27.35 | $6.92 |
| 52 Week High | $41.94 | $26.59 |
Technical Indicators
Market Signals| Indicator | MMI | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 53.33 |
| Support Level | $28.74 | $16.58 |
| Resistance Level | $29.65 | $17.62 |
| Average True Range (ATR) | 0.82 | 0.96 |
| MACD | -0.13 | -0.14 |
| Stochastic Oscillator | 13.28 | 28.83 |
Price Performance
Historical ComparisonAbout MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.